Lantheus stock saw an improvement in its IBD SmartSelect Composite Rating Monday, from 93 to 96. The medical imaging stock rockets to new highs amid robust earnings reports last Thursday. The stock sports a 99 Relative Strength Rating.
The upgrade means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength.
Lantheus stock is considered extended and is now out of buy range. Look for a pullback into a bullish pattern setup for another buying opportunity. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
See How IBD Helps You Make More Money In Stocks
One weak spot is the company's 69 EPS Rating, which tracks quarterly and annual earnings-per-share growth. Look for that to improve to 80 or better to show it's in the top 20% of all stocks.
Its Accumulation/Distribution Rating of A shows heavy buying by institutional investors over the last 13 weeks.
Lantheus Stock Soars On Q4 Results
The company posted 257% earnings-per-share growth for Q4. That marks three straight quarters of rising EPS gains. Top line growth climbed 38%, up from 15% in the prior report. That marks one quarter of increasing revenue increases.
Lantheus stock earns the No. 1 rank among its peers in the Medical-Products industry group. United Guardian and Boston Scientific are also among the group's highest-rated stocks.
